Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medicamen OrganicsNSE:MEDIORG 21 9-Day RSI is 43.52 as of Aug. 15, 2026. GuruFocus rates NSE:MEDIORG with a GF Score™ of 21/100. The stock has 11 warning signs investors should review. Among 1,046 Drug Manufacturers companies, Medicamen Organics ranks better than 75.72% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
Medicamen Organics 9-Day RSI Related Terms
NSE:MEDIORG vs ZTS: 9-Day RSI Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Medicamen Organics's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medicamen Organics 9-Day RSI vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Medicamen Organics's 9-Day RSI distribution charts can be found below:
* The bar in red indicates where Medicamen Organics's 9-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medicamen Organics (NSE:MEDIORG) has a 9-Day RSI of 43.52 as of Aug. 15, 2026. According to the industry distribution chart, Medicamen Organics ranks #254 out of 1046 companies in the Drug Manufacturers industry, placing it in the top 24.3%.
Is Medicamen Organics' 9-Day RSI too high?
Medicamen Organics' current 9-Day RSI is 43.52. The Drug Manufacturers industry median 9-Day RSI is 54.85. Medicamen Organics' value of 43.52 is 20.7% below this industry median. Based on the distribution chart, Medicamen Organics ranks #254 out of 1046 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Medicamen Organics has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Medicamen Organics' 9-Day RSI compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Medicamen Organics ranks #254 out of 1046 companies for 9-Day RSI. This places Medicamen Organics in the top 24% of its industry — outperforming the majority of peers. The industry median 9-Day RSI is 54.85. Medicamen Organics' value of 43.52 is 20.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 9-Day RSI for a Drug Manufacturers company?
The median 9-Day RSI among Drug Manufacturers companies is 54.85, based on 1,046 companies in the industry. Companies in the top quartile (top 25%) have a 9-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 9-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medicamen Organics's current 9-Day RSI of 43.52 is 20.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 9-Day RSI mean?
A high 9-Day RSI can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median 9-Day RSI is 54.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medicamen Organics's current 9-Day RSI is 43.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medicamen Organics stock overvalued right now?
Medicamen Organics (NSE:MEDIORG) has a current 9-Day RSI of 43.52. The current 9-Day RSI is 43.52 and 20.7% below the Drug Manufacturers industry median of 54.85. Medicamen Organics' overall GF Score™ is 21/100 with 11 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 9-Day RSI calculated?
9-Day RSI is calculated from a company's financial statements. For Medicamen Organics (NSE:MEDIORG), the current 9-Day RSI is 43.52 as of Aug. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Medicamen Organics Ltd develops, manufactures, and distributes a wide range of pharmaceutical dosage forms, including Tablets, Capsules, Oral Liquids, Ointments, Gel, Syrups, Suspension and Dry powders. The company operates two WHO Good Manufacturing Practice certified facilities in India, producing products for both domestic and international clients. It provides contract manufacturing and loan license services to various pharmaceutical companies and exports to several countries across Africa, CIS, and South Asia. The principal source of revenue is through the manufacturing, export, and contract services focused on generic and branded pharmaceutical formulations.
21GF Score
Get the complete analysis for NSE:MEDIORG
9-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:MEDIORG has been successfully added to your 
